Last reviewed · How we verify
Teveten (EPROSARTAN)
Teveten (EPROSARTAN) is a small molecule Angiotensin 2 Receptor Blocker that targets the Type-1 angiotensin II receptor. Originally developed by Abbvie, it was FDA approved in 1997 for the treatment of hypertensive disorder. As an off-patent medication, it is available as a generic. Teveten has a relatively short half-life of 2.1 hours and low bioavailability of 13%. It is currently owned by Abbvie.
At a glance
| Generic name | EPROSARTAN |
|---|---|
| Sponsor | AbbVie |
| Drug class | Angiotensin 2 Receptor Blocker |
| Target | Type-1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Hypertensive disorder
Common side effects
- Dizziness
- Fatigue
- Upper respiratory tract infection
- Nausea
- Dyspepsia
- Coughing
- Pharyngitis
- Rhinitis
- Bronchitis
- Diarrhea
- Abdominal pain
- Asthenia
Serious adverse events
- Atrial fibrillation
- Angina pectoris
- Myocardial infarction
- Stroke
- Syncope
- Anaphylaxis
- Hepatic dysfunction
- Renal failure
- Hyperkalemia
- Angioedema
Drug interactions
- indomethacin
- lithium
- spironolactone
- triamterene
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? (PHASE3)
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (PHASE4)
- Effect of Losartan or Eprosartan on Fructose Hyperuricemia (NA)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teveten CI brief — competitive landscape report
- Teveten updates RSS · CI watch RSS
- AbbVie portfolio CI